The global CRO market reached $44.4 billion value in 2017

Print 04 May 2018
GMP News

According to report from The Business Research Company, the global market for clinical trial services to biopharmaceutical and medical device companies is forecast to grow at 12 per cent year on year to 2021. That is an acceleration from its rate of 10 per cent up to 2017 which raised its value to $44.4 billion.

Contract research organizations (CROs) are service providers that offer solutions for the conduct of clinical trials, including initial drug discovery solutions, toxicology studies, bio-analytical services, central laboratory functions, site monitoring, data management services, vigilance, bio-statistics, study and development program design and consulting, regulatory affairs and a variety of post-marketing surveillance services. Many pharmaceutical companies already outsource their R&D activities to CROs and is expected that they will increase their outsourcing of drug development processes to CROs in future.

By service type, drug discovery was the largest segment in 2017, accounting for about 33 per cent of the CRO market. By therapeutic area, oncology was the largest segment, accounting for about 25 per cent of the total.

North America is the largest region for the production of CRO services, $18.8 billion, while CRO consumption in North America is worth $20.8 billion or about 47 per cent of the global total. The large market size can be attributed to the presence of a large number of pharmaceutical companies and extensive drug development activity in the region, especially in the USA. The production/consumption difference is due to the use of lower-cost offshore locations for some CRO activities by US pharmaceutical firms, although the majority of US outsourced activity remains within the country.

Declining growth in the pharmaceutical market is affecting the CRO industry, though not in the obvious way. Recently, the double digit growth rates of pharmaceutical and biotechnology companies have been shrinking to single digits. Pharmaceutical and biotechnology companies have been confronted with the need to minimize their drug production and development costs. This has forced most of them to evaluate cost saving options such as outsourcing. Several companies in this sector have already adopted this strategy and outsourced their processes to specialist service providers such as CROs.

IQVIA is the largest player in the global CRO market with a 12.4 per cent share, followed by Laboratory Corporation of America Holdings, ICON Plc, PAREXEL and PPD.

Source

Return